Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yvonne Kaufmann
Observed name:
Y. Kaufmann
Institution:
Molecular Partners (Switzerland)
Observed institution:
Molecular Partners (Switzerland)
ORCID:
0009-0006-8629-8187
Observed ORCID:
0009-0006-8629-8187
OpenAlex ID:
A5013176558
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
2022
·
Sylvia Rothenberger
, Daniel L. Hurdiss
, et al.
·
Nature Biotechnology
·
77
PDF
Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates
2020
·
Marcel Walser
, Sylvia Rothenberger
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
31
PDF
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
·
Cancer Immunology Research
·
17
PDF
Abstract 3251: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin®molecule for tumor-localized immune activation
2019
·
Nicolo Rigamonti
, Anja Schlegel
, et al.
·
Immunology
·
7
MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells
2022
·
Matteo Bianchi
, Christian Reichen
, et al.
·
Blood
·
5
Abstract 3251: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin®molecule for tumor-localized immune activation
2019
·
Nicolo Rigamonti
, Anja Schlegel
, et al.
·
Cancer Research
·
4
Abstract 3119: Next-generation multi-specific and conditionally activated CD3 Switch-DARPins with CD2 co-stimulation to tackle the current limitations of T cell engagers in solid tumors
2025
·
Matteo Bianchi
, Marco Franchini
, et al.
·
Cancer Research
·
1
Abstract 339: Development of 212Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors
2025
·
Stephan Wullschleger
, Amal Saidi
, et al.
·
Cancer Research
·
1
Abstract 346: MP0712, the first anti-DLL3 212Pb radio-DARPin (RDT) candidate for targeted radiotherapy of small cell lung cancer (SCLC)
2025
·
Amelie Croset
, Amal Saidi
, et al.
·
Cancer Research
·
1
MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation
2024
·
Alexander Link
, Teresa Maria Frasconi
, et al.
·
Blood
·
1
PDF
Avidity-Engineered CD3 Engaging DARPin ® Targeting Three Tumor Associated Antigens Induce Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety
2021
·
Matteo Bianchi
, Nina Reschke
, et al.
·
Blood
·
1
Abstract 1073: A tumor-targeted CD40 agonistic DARPin® molecule leading to antitumor activity with limited systemic toxicity
2020
·
Nicolo Rigamonti
, Sarah Jetzer
, et al.
·
Cancer Research
·
1
Abstract 4552: Tumor-restricted immune modulation by multispecific molecules from the DARPin toolbox
2018
·
Ulrike Fiedler
, Christian Reichen
, et al.
·
Cancer Research
·
1
Comparison of an FAP-targeted, CD137 activating DARPin drug candidate with a non-targeted, CD137 activating antibody in a human PBMC transplanted HT-29 mouse tumor model.
2017
·
Julia Hepp
, Alexander Link
, et al.
·
Journal of Clinical Oncology
·
1
1072 MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM
2026
·
Stephan Wullschleger
, Matteo Bianchi
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 1624: Logic-gated switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer
2026
·
Matteo Bianchi
, Sarah Jetzer
, et al.
·
Cancer Research
Data from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S12 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
PDF
Supplementary Figure S1 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S16 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S2 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S15 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S3 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S5 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Supplementary Figure S13 from The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells
2024
·
Matteo Bianchi
, Christian Reichen
, et al.
Show more works
View as search
Works count:
48
Citation count:
149
H-index:
5
I10-index:
3
Year
Topic
Type
